World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
53228
World Ranking
11957
National Ranking
445

Overview

Federico Cappuzzo is affiliated with the Azienda Unità Sanitaria Locale Della Romagna in Italy, focusing on medical research primarily within the fields of pulmonary and respiratory medicine and oncology. Their body of work includes a total of 410 publications centered on medicine, with notable subfields in pulmonary and respiratory medicine (168 publications) and oncology (165 publications), complemented by studies in molecular biology, cancer research, and diagnostic imaging.

Their research addresses several principal topics, with particular emphasis on lung cancer treatments and mutations, cancer immunotherapy and biomarkers, and lung cancer diagnosis and treatment. Additional interests cover cancer genomics and diagnostics, colorectal cancer treatments, and the application of radiomics and machine learning in medical imaging.

Frederico Cappuzzo has a record of publication in various professional venues, indicating a focus on thoracic oncology and related disciplines. Frequent publication venues include:

  • Journal of Thoracic Oncology (22 publications)
  • Journal of Clinical Oncology (22 publications)
  • Annals of Oncology (17 publications)
  • ESMO Open (8 publications)
  • Lung Cancer (7 publications)

Their collaborative network includes multiple frequent coauthors, highlighting extensive joint research efforts. Notable collaborators include:

  • Lorenza Landi (39 joint publications)
  • Gennaro Ciliberto (27 joint publications)
  • Enriqueta Felip (21 joint publications)
  • Filippo Tommaso Gallina (21 joint publications)
  • Simonetta Buglioni (19 joint publications)

Recent publications of Federico Cappuzzo showcase involvement in significant clinical trials and cancer treatment studies related to lung cancer:

  • "Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial," 2020, Journal of Thoracic Oncology
  • "IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC," 2021, Journal of Thoracic Oncology
  • "Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study," 2023, Annals of Oncology
  • "IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain," 2021, Journal of Thoracic Oncology
  • "Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study," 2021, Journal of Thoracic Oncology

Best Publications

  • MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Jeffrey A. Engelman;Kreshnik Zejnullahu;Tetsuya Mitsudomi;Youngchul Song

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  • Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer

    Federico Cappuzzo;Fred R. Hirsch;Elisa Rossi;Stefania Bartolini

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

    Federico Cappuzzo;Tudor Ciuleanu;Lilia Stelmakh;Saulius Cicenas

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

  • Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

    Howard J West;Michael McCleod;Maen Hussein;Alessandro Morabito

  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  • Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

    Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

    Kimio Yonesaka;Kreshnik Zejnullahu;Isamu Okamoto;Taroh Satoh

  • A genomics-based classification of human lung tumors

    Danila Seidel;Thomas Zander;Lukas C. Heukamp;Martin Peifer

  • Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

    Federico Cappuzzo;Antonio Marchetti;Margaret Skokan;Elisa Rossi

  • PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

    A D'Incecco;M. Andreozzi;V. Ludovini;E. Rossi

  • Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

    Kurtis D. Davies;Anh T. Le;Mariana F. Theodoro;Margaret C. Skokan

  • Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients

    Federico Cappuzzo;Marileila Varella-Garcia;Hisayuki Shigematsu;Irene Domenichini

  • Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

    Federico Cappuzzo;Elisabetta Magrini;Giovanni Luca Ceresoli;Stefania Bartolini

  • Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    Robert Jotte;Federico Cappuzzo;Ihor Vynnychenko;Daniil Stroyakovskiy

Frequent Co-Authors

Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Martin Reck
Martin Reck LungenClinic Grosshansdorf
Armando Santoro
Armando Santoro Humanitas University
Gabriella Fontanini
Gabriella Fontanini University of Pisa
Tony Mok
Tony Mok Chinese University of Hong Kong
Pasi A. Jänne
Pasi A. Jänne Harvard University
Fiona H Blackhall
Fiona H Blackhall University of Manchester
Andrea Ardizzoni
Andrea Ardizzoni University of Bologna
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Egbert F. Smit
Egbert F. Smit VU University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring career opportunities related to medicine in the USA often leads students to consider flexible online degree options. For nurses looking to advance their qualifications, bridge programs such as the rn to np bridge program make it possible to transition from an RN to a Nurse Practitioner through online study. Similarly, registered nurses who prefer to avoid additional clinical hours may benefit from rn to bsn programs no clinicals, offering a convenient route to further credentials.

For those interested in wellness, an online nutritionist degree is an excellent way to enter the growing field of nutrition and public health. Meanwhile, students aspiring for leadership in healthcare administration should consider applying to top cahme accredited mha programs, which are respected for their rigorous standards and flexible online formats.

With these degree pathways, students can advance their careers and broaden their impact on healthcare while balancing work and personal commitments.

Best Scientists Citing Federico Cappuzzo

Trending Scientists

Recently Published Articles